Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
A multidisciplinary, international group of experts discussed the current status and future directions of MCI, with regard to clinical presentation, cognitive and functional assessment, and the role of neuroimaging, biomarkers and genetics.
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects.
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
The rationales behind and the diagnostic performances of the core cerebrospinal fluid biomarkers for AD, namely total tau, phosphorylated tau and the 42 amino acid form of amyloid-β are presented.
CSF markers for incipient Alzheimer's disease
Gut microbiome alterations in Alzheimer’s disease
The gut microbiome of AD participants has decreased microbial diversity and is compositionally distinct from control age- and sex-matched individuals, which adds AD to the growing list of diseases associated with gut microbial alterations, as well as suggest that gut bacterial communities may be a target for therapeutic intervention.
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Biological analysis of the 18 proteins found in blood plasma points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
- S. Salloway, R. Sperling, H. Brashear
- Medicine, PsychologyNew England Journal of Medicine
- 23 January 2014
Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers.